Cellontech Logo

서브비주얼 서브비주얼

History

Unceasing technological innovation shapes
CELLONTECH's past, present, and future.

History

Since its establishment in 2000, CELLONTECH has been committed to continuous growth and innovation in the field of BioCollagen and related product research and development. Presently, the company is vigorously pursuing global market entry and expansion with its independently

  • 2023
    06
    • [CartiZol] Obtained marketing auth
    • Begin B2C business with official launching of 'Oligochak glutathione film'
    • [CartiSeal] officially launched and marketed
    01
    • [CartiZol] Prime officially launched and marketed
  • 2022
    09
    • [CartiZol] Extra Signed a sales contract with LG Chem
    05
    • [CartiFill] Obtained medical device marketing approval from the Health Sciences Authority (HSA) of Singapore and the Thai Food and Drug Administration (Thai FDA)
    01
    • Registered as a venture business
  • 2021
    06
    • [CartiZol] officially launched and marketed
    04
    • [CartiZol] Passed New Health Technology Assessment (NECA)
  • 2020
    11
    • ISO 13485:2016 (Quality Management System) certified
  • 2019
    05
    • National health insurance coverage for [Chondron] expanded, groundbreaking ceremony for ‘RMS CAMP’ and proclamation ceremony for ‘RMS Innovation 2028’ global vision held
  • 2018
    06
    • [Chondron] kicked off Phase 3 clinical trials in Japan, ‘Regenerative Medical System Center for Innovation’ established
  • 2017
    06
    • Selected as one of 52 delegation to accompany the President's visit to the White House
    05
    • 'ATELOCOLLAGEN-D.F.' registered in FDA DMF (Drug Master Files)
    04
    • [RegenPatch] gained marketing approval from the Ministry of Food and Drug Safety (MFDS) of Korea
    • Selected as ‘2016 Biopharmaceutical Industrial Development Contribution Corporation’ and awarded the ‘Minister of Health and Welfare Accolade’
    03
    • 'Theraform-D' preclinical research conducted jointly with Columbia University
  • 2016
    05
    • 'ATELOCOLLAGEN-D.F.' registered in ICID (International Cosmetic Ingredient Dictionary and Handbook) of PCPC (The Personal Care Products Council)
    01
    • [CartiZol] acquried NET (New Excellent Technology) cert.
  • 2015
    12
    • High concentration [BioCollagen] patent registered in Korea (‘High concentration collagen production method’ / Reg. No.: 10-1576060)
    01
    • [RegenSeal] officially launched and marketed
  • 2014
    12
    • ISO22716 (Cosmetic GMP - Quality System Management) obtained
    11
    • High concentration BioCollagen filler [LUCIZEN] marketing approval received from MFDS
    • Prime Minister's Commendation received on the 28th 'Day of Medicine' (hosted by Korean Pharmaceutical Association)
    07
    • ‘BioCollagen Powder’ listed in DMF (FDA)
    04
    • Received the Presidential award on the 42nd World Health Day (Ministry of Health and Welfare)
    02
    • [CartiFill] officially launched and marketed
    01
    • [CartiFill] received HTA (Health Technology Assessment) approval from NECA(National Evidence-based Healthcare Collaboration Agency)
  • 2013
    06
    • [CartiZol]·[RegenSeal] marketing approval obtained
    03
    • [CartiFill] marketing approval received
    • RMS Phytostem Panax Ginseng, SCE Phytostem Camellia Sinensis and SCE Phytostem Solanum Lycoperscium registered in ICID of PCPC
  • 2012
    09
    • [TheraFill] marketing approval received in Argentina by ANMAT
    • Gel-type [Chondron] received HTA approval from Ministry of Health and Welfare
    01
    • [BabyCell] approved for private cord blood banking service by Ministry of Health and Welfare
    • [OssFill]·[SurgiFill] marketing approval received
  • 2011
    09
    • [TheraForm] marketing approval
    • [OssFill (Biomimetic Bone Supplement)] CE MDD approval
  • 2010
    05
    • [TheraFill] officially launched and marketed
  • 2009
    11
    • CE mark obtained for [CartiFill], [DuoFill], [MRM Kit] and [SurgiFill]
    08
    • [RMS Ossron] marketing approval received
  • 2008
    05
    • [BioCollagen] registered in ICID (PCPC)
    • Held [Chondron] surgical training workshop for the Royal National Orthopaedic Hospital (RNOH) in England
    04
    • [BioCollagen] registered in DMF (FDA)
  • 2007
    12
    • Designated as ATC (Advanced Technology Center) by Ministry of Commerce, Industry and Energy
    10
    • BioCollagen wound healing dressing [TheraForm] received CE approval
  • 2006
    12
    • ISO13485 certification received
    11
    • [BioCollagen] filler manufacturing facility construction complated (Seongsu production facility)
  • 2005
    10
    • [RMS Ossron] received 2005 New Technology Korea Excellence Award (Ministry of Commerce, Industry and Energy)
  • 2004
    03
    • [Chondron] received IR52 Jang Young Sil award and obtained KT (Excellent Korean Technology) certification
  • 2003
    12
    • [RMS Ossron] Selected as the next generational world-class product by Ministry of Commerce, Industry and Energy (2003)
    10
    • [Chondron] awarded the silver medal from 2003 New Technology Korea
  • 2002
    07
    • [BabyCell] cord blood bank service launched
    03
    • [Chondron] listed on national health insurance coverage
  • 2001
    02
    • Facility KGMP certified
    01
    • [Chondron], Autologous Chondrocyte Implantation, approved as the first bioengineering product
  • 2000
    04
    • Regenerative Medical System division and cell therapy production facility established
  • 1996
    04
    • Tissue Engineering Research Association established